Cyclacel Pharmaceuticals (CYCC) Proxy Filing summary

Executive summary

• Special Meeting called to approve key transactions, including new equity issuances, capital structure changes, and governance amendments.

• David Lazar to acquire Series C and D Preferred Stock for $3.1 million, convertible into significant common stock holdings, subject to shareholder approval.

• Board determined these transactions are necessary to address liquidity needs and Nasdaq compliance, and to avoid potential liquidation.

• Warrant Exchange Agreement with Armistice Capital to simplify capital structure and eliminate warrants for 24.8 million shares.

• Board unanimously recommends approval of all proposals to ensure continued operations and Nasdaq listing.

Voting matters and shareholder proposals

• Proposal 1: Approve issuance of common stock to David Lazar upon conversion of preferred stock and remove Series C Ownership Limitation.

• Proposal 2: Approve issuance of common stock in connection with the Warrant Exchange Agreement.

• Proposal 3: Approve a reverse stock split at a ratio between 1:4 and 1:16.

• Proposal 4: Approve increase in authorized common stock from 100 million to 250 million shares.

• Proposal 5: Approve amendment to 2018 Equity Incentive Plan to add 500,000 shares.

• Proposal 6: Approve adjournment of the meeting if more time is needed to solicit votes.

Board of directors and corporate governance

• Board has fixed January 6, 2025 as the record date for voting eligibility.

• If proposals pass, David Lazar will become the largest stockholder and the company will be a "controlled company" under Nasdaq rules, reducing requirements for board independence.

• Board and management recommend voting in favor of all proposals.